Resources

High–quality evidence assessing single–dose HPV vaccination suggests that implementing a single–dose schedule is scientifically sound, and provides the greatest public health benefit.A single–dose HPV vaccination schedule has the potential to reach more girls and avert a greater number of cervical cancer cases than reaching fewer girls with a two–dose regimen.This brief provides a list of frequently asked questions and answers about the evidence around single–dose HPV vaccination, and the current policy landscape.

The World Health Organization recommends the programmatic use of two vaccines, RTS,S/AS01 and R21/Matrix-M, for the prevention of Plasmodium falciparum malaria in children living in malaria-endemic areas—prioritizing areas of moderate and high transmission. More than 28 countries have expressed interest in introducing a malaria vaccine, and most are actively moving toward introduction. This fact sheet reviews the two vaccines side-by-side, to examine how the two products are similar and how they differ to aid in country decision-making.

The World Health Organization (WHO) recommends the programmatic use of two vaccines, RTS,S/AS01 and R21/Matrix-M, for the prevention of Plasmodium falciparum malaria in children living in malaria-endemic areas—prioritizing areas of moderate and high transmission. This fact sheet provides an overview of the evidence that informed WHO to make their recommendation of R21, as well as a summary of the development history of and clinical evidence on R21.

The World Health Organization (WHO) recommends the programmatic use of two vaccines, RTS,S/AS01 and R21/Matrix-M, for the prevention of Plasmodium falciparum malaria in children living in malaria-endemic areas—prioritizing areas of moderate and high transmission. This fact sheet provides an overview of the development history of RTS,S, the impact of and evidence from the RTS,S pilot program conducted in Ghana, Kenya, and Malawi, and recent results from a study on the seasonal use of RTS,S.

Malaria is a major public health problem in the Democratic Republic of the Congo (DRC). It is the leading cause of morbidity and mortality in DRC, with 27.3 million cases of malaria and 24,880 malaria deaths reported in 2022.An effective surveillance, monitoring and evaluation (M&E) system that produces high quality data is essential for the monitoring of malaria trends, evaluation of the impact of malaria control interventions, and evidence-based decision-making. Problems with the quality of malaria data persist in the DRC, limiting the national malaria control program’s (NMCP) informed decision-making and ability to launch a timely response to identified priorities.To address this need, the DRC NMCP – with support from PATH MACEPA – has developed a decentralized routine data quality audit (RDQA) process that was piloted in four health zones in Haut-Katanga. Pilot methodology, preliminary results, and key recommendations are summarized in this technical brief.